newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)

-Seelos is conducting a Phase I ethnobridging study in healthy Japanese and non-Asian subjects to evaluate the safety and pharmacokinetic profiles of SLS-002. NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Seelos Therapeutics,